The FDA has released guidance to help drug manufacturers effectively respond to Form 483 observations issued after CGMP inspections, ensuring stronger compliance and faster resolution of regulatory issues.

The guidance outlines best practices for preparing written responses, including clear structure, timely submission, and complete supporting documentation. Public comments are open until 08 May 2026.

Key recommendations include thoroughly understanding each observation, assigning management responsibility, and conducting detailed investigations. Companies are advised to develop robust Corrective and Preventive Action (CAPA) plans and assess their effectiveness.

The document also provides guidance on handling scientific or technical disagreements with FDA findings, along with expectations for communication, attachments, and response formatting.

This update supports pharmaceutical manufacturers in improving CGMP compliance, strengthening inspection readiness, and minimizing regulatory risk.